Clinical-Stage Biopharmaceutical  ·  AUD & Substance Use

A patented oral neuroplastogen
for alcohol use disorder.

DMX-1001 is an investigational new chemical entity with granted composition-of-matter and method-of-use patents, a completed Phase 1a MAD trial, and an active Phase 1b program targeting the 29 million Americans living with AUD.

View Progress Investor Relations
Complete
Phase 1a MAD Trial
Safety & PK confirmed
Active
Phase 1b Trial
PK/PD · healthy volunteers
Granted
Core IP Portfolio
Composition · methods · formulations
Awarded
NIH Grant — $1.7M
Non-dilutive · NIH
Clinical Progress
✓
Complete
Phase 1a
MAD Trial

Multiple Ascending Dose trial of DMX-1001 successfully completed, confirming a favorable safety and tolerability profile.

TrialPhase 1a · MAD
EndpointSafety & pharmacokinetics
●
Active
Phase 1b
Trial Underway

Ongoing trial evaluating pharmacokinetics, pharmacodynamics, and safety of DMX-1001 in healthy volunteers.

TrialPhase 1b · PK/PD
SubjectsHealthy volunteers
◈
Granted
Core IP
Portfolio

Granted patents covering composition of matter, methods of use, combination therapies, and synthetic processes protect DMX-1001.

PatentsComposition · methods
CoverageFormulations · combinations
◈
Awarded
NIH Grant
$1.7 Million

National Institutes of Health non-dilutive grant awarded, providing independent validation of DemeRx's science and clinical approach.

SourceNat. Institutes of Health
TypeNon-dilutive funding
29M
Americans with AUD
<5%
Currently using medication
80%
Relapse rate within 1 year
$250B
Annual economic burden
Investor Relations →
Why DMX-1001 — And Why Now

DMX-1001 is oral noribogaine — the active metabolite of ibogaine — engineered to deliver neuroplastic benefit without the liabilities that have held the class back. The differentiation is as much about safety and deliverability as it is about mechanism.

01 — Deliverability

Oral, controlled exposure

DMX-1001 is an oral formulation designed for controlled, repeatable dosing — not a single acute psychedelic session. That makes it a fit for real-world AUD treatment and for a conventional clinical and commercial path.

Phase 1a PK confirmed
02 — Mechanism

Neuroplasticity, not euphoria

As the active metabolite of ibogaine, noribogaine targets structural neuroplasticity in the brain's addiction circuitry — delivering therapeutic effect without the euphoric or addictive properties associated with conventional psychedelics.

Non-hallucinogenic neuroplastogen
03 — Safety governance

Cardiac safety, overseen

The ibogaine class carries known cardiac considerations. DemeRx addresses this head-on: Phase 1a MAD confirmed a favorable safety and tolerability profile, with cardiology oversight led at board level by Pascal Goldschmidt, MD.

Board-level cardiology oversight
Catalysts & The Raise
Completed
Phase 1a MAD trial — safety & PK confirmed
✓ De-risked
[Target: Q_ 20__]
Phase 1b PK/PD readout — healthy volunteers
● Active · next catalyst
Planned
Phase 2 proof-of-concept — alcohol use disorder
○ This round enables
Pipeline
Expansion — opioid & cocaine use disorder
○ Preclinical · platform upside
Current Financing
Raising $[ •• ]M
Series [ _ ]
  • Complete the active Phase 1b PK/PD trial
  • Initiate Phase 2 proof-of-concept in AUD
  • Advance CMC, formulation & the granted IP portfolio
  • Extend DMX-1001 into opioid & cocaine use disorder
Expected to fund operations through [key milestone / date]. Detailed materials available to qualified investors under NDA.
Request the Data Room
Investor Relations

Clinical-stage.
Patent-protected.
Actively enrolling.

DemeRx is advancing DMX-1001 through a rigorous clinical development program. This section provides current program status, pipeline, press releases, and direct IR contact.

Phase 1a — Complete
Phase 1b — Active
IP Portfolio — Granted
NIH Grant — $1.7M
Clinical & Preclinical Pipeline
Asset / Indication Preclinical Phase 1a Phase 1b Phase 2 Phase 3
DMX-1001
Alcohol Use Disorder
Oral noribogaine · NCE
Complete
Active
Planned
DMX-1001
Opioid Use Disorder
Oral noribogaine · NCE
Planned
DMX-1001
Cocaine Use Disorder
Oral noribogaine · NCE
Planned
Recent Press Releases
Press Release
DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for AUD
January 2025→
Press Release
DemeRx Awarded $1.7 Million National Institutes of Health Grant
November 2024→
Press Release
DemeRx Welcomes E. Matthew "Whiz" Buckley to Advisory Board
July 2024→
Investor Materials
Corporate Presentation

Request the
investor deck.

Our corporate presentation covers program status, preclinical and clinical data, IP position, market opportunity, and team credentials. Available to qualified investors under NDA.

Request Deck Contact IR
29M
U.S. patients with AUD
$250B
Annual economic burden
<5%
Currently use medication
4+
Granted patent families
Leadership, Board & Advisors

DemeRx is led by the scientist who pioneered noribogaine and holds its foundational patents, backed by a board that pairs drug-development and commercial experience with dedicated cardiology and psychiatry oversight.

Deborah Mash
Deborah C. Mash, PhD
CEO, President & Founder
Original noribogaine patent holder · 30+ yrs research
Mark Ellison
Mark Ellison, PhD
President, Clinical Operations & Chief Development Officer
E. Douglas Kramer
E. Douglas Kramer, MD
VP, Clinical & Regulatory Affairs
John C. Thomas Jr.
John C. Thomas Jr.
Chief Financial Officer & Secretary
Board of Directors
Richard Serbin
Richard S. Serbin, Esq.
Executive Chairman
Christopher Hassan
Christopher Hassan
Board Chairperson
Pascal Goldschmidt
Pascal J. Goldschmidt, MD
Director · Lead Consultant, Cardiology
Cardiac safety oversight
Heather Callander-Potters
Heather Callander-Potters, MBA
Director
Guy Bolton
Guy Bolton
Director
Vic Pirotsky
Vic Pirotsky
Director
Scientific & Strategic Advisors
Bryon Adinoff
Bryon Adinoff, MD
Lead Consultant, Psychiatry
Matthew Buckley
Matthew ‘Whiz’ Buckley
Board Advisor
Hans Hertell
Amb. Hans Hertell
Board Advisor
Contact Investor Relations
Chief Financial Officer
John C. Thomas Jr.
Chief Financial Officer and Secretary
DemeRx, Inc.
Emailir@demerx.com Webdemerx.com
Chief Executive Officer & Founder
Deborah C. Mash, PhD
CEO, President & Founder · 30+ years noribogaine research · Original patent holder
Emaildmash@demerx.com LinkedInlinkedin.com/company/demerx-inc
ℹ

For institutional investors and qualified purchasers: DemeRx is a private clinical-stage company. Securities information is provided only to accredited investors under applicable securities laws. Media inquiries: media@demerx.com